You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEthotoin
Accession NumberDB00754  (APRD00962)
TypeSmall Molecule
GroupsApproved
DescriptionEthotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin is no longer commonly used.
Structure
Thumb
Synonyms
(+-)-3-Ethyl-5-phenylhydantoin
1-Ethyl-2,5-dioxo-4-phenylimidazolidine
3-Ethyl-5-phenyl-2,4-imidazolidinedione
3-Ethyl-5-phenyl-imidazolidine-2,4-dione
3-Ethyl-5-phenylhydantoin
3-Ethyl-5-phenylimidazolidin-2,4-dione
Ethotoin
Ethotoïne
Ethotoinum
Etotoina
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PeganoneTablet250 mg/1OralRECORDATI RARE DISEASES, INC.1957-04-22Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AccenonDainippon Sumitomo
PegoanoneNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII46QG38NC4U
CAS number86-35-1
WeightAverage: 204.2252
Monoisotopic: 204.089877638
Chemical FormulaC11H12N2O2
InChI KeySZQIFWWUIBRPBZ-UHFFFAOYSA-N
InChI
InChI=1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15)
IUPAC Name
3-ethyl-5-phenylimidazolidine-2,4-dione
SMILES
CCN1C(=O)NC(C1=O)C1=CC=CC=C1
Pharmacology
IndicationFor the control of tonic-clonic (grand mal) and complex partial (psychomotor) seizures.
Structured Indications
PharmacodynamicsEthotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges.
Mechanism of actionThe mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin inhibits nerve impulses in the motor cortex by lowering sodium ion influx, limiting tetanic stimulation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium channel protein type 5 subunit alphaProteinyes
inhibitor
HumanQ14524 details
Related Articles
AbsorptionFairly rapidly absorbed, however, the extent of oral absorption is not known.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic. The drug exhibits saturable metabolism with respect to the formation of N-deethyl and p-hydroxyl-ethotoin, the major metabolites.

SubstrateEnzymesProduct
Ethotoin
Not Available
p-Hydroxyl-ethotoinDetails
Route of eliminationNot Available
Half life3 to 9 hours
ClearanceNot Available
ToxicitySymptoms of overdose include drowsiness, loss of or impaired muscle coordination, nausea, visual disturbance, and, at very high doses, coma.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Ethotoin is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ethotoin.Experimental
AcenocoumarolEthotoin may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Ethotoin.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ethotoin.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Ethotoin.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ethotoin.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Ethotoin.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ethotoin.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ethotoin.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethotoin.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ethotoin.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ethotoin.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethotoin.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ethotoin.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Ethotoin.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethotoin.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Ethotoin.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ethotoin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Ethotoin.Vet Approved
AzelastineEthotoin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Ethotoin.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Ethotoin.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Ethotoin is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ethotoin.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Ethotoin.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ethotoin is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Ethotoin.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethotoin.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Ethotoin.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethotoin.Approved, Investigational
BuprenorphineEthotoin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethotoin.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethotoin.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Ethotoin.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Ethotoin.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Ethotoin.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Ethotoin.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethotoin.Approved, Illicit, Vet Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethotoin.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ethotoin.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Ethotoin.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethotoin.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ethotoin.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ethotoin.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethotoin.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Ethotoin.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethotoin.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethotoin.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethotoin.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ethotoin.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Ethotoin.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethotoin.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Ethotoin is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Ethotoin.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Ethotoin is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Ethotoin.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Ethotoin.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Ethotoin.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethotoin.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethotoin.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ethotoin.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ethotoin.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethotoin.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ethotoin.Approved
DantroleneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethotoin.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Ethotoin.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethotoin.Approved
DesipramineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Ethotoin.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethotoin.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethotoin.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ethotoin.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethotoin.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ethotoin.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ethotoin.Approved, Illicit, Vet Approved
DicoumarolEthotoin may increase the anticoagulant activities of Dicoumarol.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethotoin.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethotoin.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethotoin.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethotoin.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethotoin.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Ethotoin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Ethotoin.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Ethotoin.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethotoin.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Ethotoin.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Ethotoin.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ethotoin.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ethotoin.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Ethotoin.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Ethotoin is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ethotoin.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethotoin.Approved
EthanolEthotoin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethotoin.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethotoin.Approved
Ethyl biscoumacetateEthotoin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ethotoin.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ethotoin.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethotoin.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Ethotoin.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Ethotoin.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Ethotoin.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethotoin.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Ethotoin.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Ethotoin is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethotoin.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethotoin.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ethotoin.Approved, Illicit
FluindioneEthotoin may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ethotoin.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethotoin.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethotoin.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethotoin.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ethotoin.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Ethotoin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ethotoin.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Ethotoin.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethotoin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ethotoin is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ethotoin.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Ethotoin is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Ethotoin.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ethotoin.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethotoin.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ethotoin.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Ethotoin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethotoin.Approved
HydrocodoneEthotoin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethotoin.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ethotoin.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Indalpine.Investigational, Withdrawn
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ethotoin.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethotoin.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ethotoin.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ethotoin.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethotoin.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ethotoin.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethotoin.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethotoin.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ethotoin.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Ethotoin.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Ethotoin.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Ethotoin.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethotoin.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethotoin.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Ethotoin.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethotoin.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Ethotoin.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Ethotoin.Vet Approved
MefloquineThe therapeutic efficacy of Ethotoin can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Ethotoin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Ethotoin.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethotoin.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethotoin.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethotoin.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ethotoin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ethotoin.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ethotoin.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ethotoin.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Ethotoin.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethotoin.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethotoin.Approved
MethotrimeprazineEthotoin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethotoin.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethotoin.Approved
MetyrosineEthotoin may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Ethotoin can be decreased when used in combination with Mianserin.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethotoin.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Ethotoin is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved, Investigational
MirtazapineEthotoin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Ethotoin.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ethotoin.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethotoin.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethotoin.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ethotoin.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Ethotoin.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ethotoin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethotoin.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethotoin.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Ethotoin.Approved, Illicit
OrlistatThe serum concentration of Ethotoin can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineEthotoin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Ethotoin.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethotoin.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ethotoin.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ethotoin.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethotoin.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethotoin.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethotoin.Approved
ParaldehydeEthotoin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethotoin.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethotoin.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
PerazineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Ethotoin.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethotoin.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethotoin.Approved
PhenindioneEthotoin may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethotoin.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Ethotoin.Approved
PhenprocoumonEthotoin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Ethotoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethotoin.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ethotoin.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pomalidomide.Approved
PramipexoleEthotoin may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Ethotoin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Ethotoin.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ethotoin.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ethotoin.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ethotoin.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethotoin.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ethotoin.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ethotoin.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ethotoin.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Ethotoin.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ethotoin.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Ethotoin.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ethotoin.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethotoin.Approved
RacloprideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethotoin.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethotoin.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethotoin.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethotoin.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Ethotoin.Vet Approved
RopiniroleEthotoin may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethotoin.Approved
RotigotineEthotoin may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ethotoin.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ethotoin.Experimental
Sage 547The risk or severity of adverse effects can be increased when Ethotoin is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethotoin.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethotoin.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Ethotoin.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethotoin.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
StiripentolThe risk or severity of adverse effects can be increased when Ethotoin is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethotoin.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethotoin.Approved
SuvorexantEthotoin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethotoin.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Ethotoin.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ethotoin.Investigational
ThalidomideEthotoin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethotoin.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethotoin.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethotoin.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethotoin.Approved
TiagabineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Ethotoin.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ethotoin.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ethotoin.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Ethotoin.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethotoin.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ethotoin.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethotoin.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ethotoin.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethotoin.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethotoin.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethotoin.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ethotoin.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ethotoin.Approved
Uc1010The risk or severity of adverse effects can be increased when Ethotoin is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ethotoin.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ethotoin.Approved
WarfarinEthotoin may increase the anticoagulant activities of Warfarin.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Ethotoin.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethotoin.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethotoin.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Ethotoin.Vet Approved
ZolpidemEthotoin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ethotoin.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Ethotoin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethotoin.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Close, W.J.; U.S. Patent 2,793,157; May 21, 1957; assigned to Abbott Laboratories.

General References
  1. SCHWADE ED, RICHARDS RK, EVERETT GM: Peganone, a new antiepileptic drug. Dis Nerv Syst. 1956 May;17(5):155-8. [PubMed:13317788 ]
External Links
ATC CodesN03AB01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9936
Caco-2 permeable+0.5629
P-glycoprotein substrateNon-substrate0.592
P-glycoprotein inhibitor INon-inhibitor0.8358
P-glycoprotein inhibitor IINon-inhibitor0.9401
Renal organic cation transporterNon-inhibitor0.8532
CYP450 2C9 substrateNon-substrate0.7507
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7383
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.914
CYP450 2D6 inhibitorNon-inhibitor0.9619
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8591
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8483
Ames testNon AMES toxic0.7056
CarcinogenicityNon-carcinogens0.8655
BiodegradationNot ready biodegradable0.8423
Rat acute toxicity2.1653 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.886
hERG inhibition (predictor II)Non-inhibitor0.8724
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Lundbeck inc
Packagers
Dosage forms
FormRouteStrength
TabletOral250 mg/1
Prices
Unit descriptionCostUnit
Peganone 250 mg tablet1.33USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point94 °CPhysProp
water solubility5280 mg/LNot Available
logP1.05SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility2.38 mg/mLALOGPS
logP1.11ALOGPS
logP1.07ChemAxon
logS-1.9ALOGPS
pKa (Strongest Acidic)11.29ChemAxon
pKa (Strongest Basic)-8.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.41 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity55.05 m3·mol-1ChemAxon
Polarizability20.68 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.5 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0udi-6920000000-01714c9dcd6c4cf02362View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzolidines
Sub ClassImidazolidines
Direct ParentPhenylhydantoins
Alternative Parents
Substituents
  • 5-phenylhydantoin
  • Phenylimidazolidine
  • Ureide
  • Benzenoid
  • Monocyclic benzene moiety
  • Urea
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function:
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is respon...
Gene Name:
SCN5A
Uniprot ID:
Q14524
Molecular Weight:
226937.475 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Lenkowski PW, Ko SH, Anderson JD, Brown ML, Patel MK: Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin. Eur J Pharm Sci. 2004 Apr;21(5):635-44. [PubMed:15066664 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23